Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1942 1
1943 1
1944 1
1945 5
1946 4
1948 1
1949 1
1951 1
1952 1
1954 1
1955 1
1968 1
1973 1
1975 1
1978 1
1979 1
1980 2
1981 2
1982 4
1983 2
1985 1
1987 2
1988 2
1989 6
1990 5
1991 2
1992 3
1993 3
1994 2
1995 2
1996 4
1997 1
1998 4
1999 4
2000 4
2001 7
2002 9
2003 10
2004 10
2005 15
2006 9
2007 8
2008 12
2009 19
2010 22
2011 35
2012 48
2013 42
2014 57
2015 24
2016 39
2017 55
2018 74
2019 94
2020 90
2021 103
2022 102
2023 110
2024 102
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,114 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, Kojima T, Metges JP, Li Z, Kim SB, Cho BC, Mansoor W, Li SH, Sunpaweravong P, Maqueda MA, Goekkurt E, Hara H, Antunes L, Fountzilas C, Tsuji A, Oliden VC, Liu Q, Shah S, Bhagia P, Kato K; KEYNOTE-590 Investigators. Sun JM, et al. Among authors: shah ma. Lancet. 2021 Aug 28;398(10302):759-771. doi: 10.1016/S0140-6736(21)01234-4. Lancet. 2021. PMID: 34454674 Clinical Trial.
Gastric cancer epidemiology and risk factors.
Guggenheim DE, Shah MA. Guggenheim DE, et al. Among authors: shah ma. J Surg Oncol. 2013 Mar;107(3):230-6. doi: 10.1002/jso.23262. Epub 2012 Nov 5. J Surg Oncol. 2013. PMID: 23129495 Review.
Improving outcomes in patients with oesophageal cancer.
Shah MA, Altorki N, Patel P, Harrison S, Bass A, Abrams JA. Shah MA, et al. Nat Rev Clin Oncol. 2023 Jun;20(6):390-407. doi: 10.1038/s41571-023-00757-y. Epub 2023 Apr 21. Nat Rev Clin Oncol. 2023. PMID: 37085570 Review.
Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma.
Shitara K, Shah MA, Lordick F, Van Cutsem E, Ilson DH, Klempner SJ, Kang YK, Lonardi S, Hung YP, Yamaguchi K, Enzinger P, Nakajima T, Matsangou M, Cao Y, Li R, Moran D, Pophale R, Oh M, Ranganath R, Ajani JA, Xu RH. Shitara K, et al. Among authors: shah ma. N Engl J Med. 2024 Sep 26;391(12):1159-1162. doi: 10.1056/NEJMc2409512. Epub 2024 Sep 16. N Engl J Med. 2024. PMID: 39282934 No abstract available.
Dietary fructose improves intestinal cell survival and nutrient absorption.
Taylor SR, Ramsamooj S, Liang RJ, Katti A, Pozovskiy R, Vasan N, Hwang SK, Nahiyaan N, Francoeur NJ, Schatoff EM, Johnson JL, Shah MA, Dannenberg AJ, Sebra RP, Dow LE, Cantley LC, Rhee KY, Goncalves MD. Taylor SR, et al. Among authors: shah ma. Nature. 2021 Sep;597(7875):263-267. doi: 10.1038/s41586-021-03827-2. Epub 2021 Aug 18. Nature. 2021. PMID: 34408323 Free PMC article.
ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.
Klempner SJ, Lee KW, Shitara K, Metges JP, Lonardi S, Ilson DH, Fazio N, Kim TY, Bai LY, Moran D, Yang J, Arozullah A, Park JW, Raizer JJ, Bang YJ, Shah MA. Klempner SJ, et al. Among authors: shah ma. Clin Cancer Res. 2023 Oct 2;29(19):3882-3891. doi: 10.1158/1078-0432.CCR-23-0204. Clin Cancer Res. 2023. PMID: 37490286 Free PMC article. Clinical Trial.
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline.
Shah MA, Kennedy EB, Alarcon-Rozas AE, Alcindor T, Bartley AN, Malowany AB, Bhadkamkar NA, Deighton DC, Janjigian Y, Karippot A, Khan U, King DA, Klute K, Lacy J, Lee JJ, Mehta R, Mukherjee S, Nagarajan A, Park H, Saeed A, Semrad TJ, Shitara K, Smyth E, Uboha NV, Vincelli M, Wainberg Z, Rajdev L. Shah MA, et al. J Clin Oncol. 2023 Mar 1;41(7):1470-1491. doi: 10.1200/JCO.22.02331. Epub 2023 Jan 5. J Clin Oncol. 2023. PMID: 36603169
Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer.
Goc J, Lv M, Bessman NJ, Flamar AL, Sahota S, Suzuki H, Teng F, Putzel GG; JRI Live Cell Bank; Eberl G, Withers DR, Arthur JC, Shah MA, Sonnenberg GF. Goc J, et al. Among authors: shah ma. Cell. 2021 Sep 16;184(19):5015-5030.e16. doi: 10.1016/j.cell.2021.07.029. Epub 2021 Aug 17. Cell. 2021. PMID: 34407392 Free PMC article.
1,114 results